Drug Profile
Research programme: beta catenin antagonist peptides - Sapience Therapeutics
Alternative Names: β-catenin antagonist programme - Sapience TherapeuticsLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Sapience Therapeutics
- Class Antineoplastics; Immunotherapies; Peptides; Peptidomimetics
- Mechanism of Action Apoptosis stimulants; Beta catenin inhibitors; Wnt signalling pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological malignancies
- No development reported Solid tumours
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 08 Feb 2021 Anticancer therapeutics - Sapience Therapeutics is available for licensing as of 08 Feb 2021. https://www.sapiencetherapeutics.com/pipeline/-catenin-antagonist (Sapience Therapeutics pipeline, February 2021)
- 01 Feb 2021 Preclinical trials in Haematological malignancies in USA (unspecified route) (Sapience Therapeutics pipeline, February 2021)